Imagine a world where a simple month-long treatment could revolutionize the lives of patients with atrial fibrillation (AF) undergoing a procedure called PCI. But here's the catch: it's not as straightforward as it seems, and the debate is heating up!
One Month vs. One Year: A Controversial Choice?
The OPTIMA-AF trial, presented at the American Heart Association's 2025 Scientific Sessions, suggests that a month of dual therapy with a direct oral anticoagulant (DOAC) and a P2Y12 inhibitor might be just as effective as a year-long treatment, with significantly fewer bleeding risks.
Dr. Yohei Sotomi's findings indicate a 5.4% rate of death or thromboembolic events with short-duration therapy compared to 4.5% with the year-long treatment, a difference within the non-inferiority margin. Moreover, major bleeding incidents were notably reduced with the shorter treatment duration.
But here's where it gets controversial: the trial's event rates were much lower than expected, which some experts argue may impact the interpretation of results. Dr. Sana Al-Khatib, an electrophysiologist, acknowledges the trial's importance but expresses caution, stating, "I personally won't change my practice based on these results."
The OPTIMA-AF trial enrolled patients with AF and CAD who required PCI. The primary efficacy endpoint was a composite of all-cause death, MI, definite stent thrombosis, stroke, or systemic embolism. Interestingly, the trial found no significant differences between the treatment groups for any of these individual components.
However, the primary safety endpoint, ISTH major or clinically relevant non-major bleeding, favored the shorter-duration dual antithrombotic therapy.
And this is the part most people miss: the trial's limitations. The lower-than-expected event rate and the inclusion of predominantly East Asian patients, who have unique risk profiles, may limit the generalizability of the findings.
Dr. Manesh Patel, president-elect of the AHA, highlights the evolving landscape of clinical trials and the need for diverse patient populations to ensure the applicability of findings.
So, the question remains: should we embrace the potential benefits of a shorter treatment duration, or do we need more evidence before making a shift in clinical practice?
What's your take on this? Share your thoughts in the comments below!
